GPT Healthcare Ltd
NSE: GPTHEALTH BSE: 544131Healthcare
Incorporated in 1989, GPT Healthcare Ltd is engaged in running hospitals and providing medical services[1]
₹138
52W: ₹114 — ₹185
PE 28 · Book ₹30.9 · +347% vs bookMarket Cap₹1,135 Cr
Stock P/E28Price to Earnings
ROCE27.2%Return on Capital
ROE21.3%Return on Equity
Div. Yield1.83%Face Value ₹10
Strengths
- +Company has been maintaining a healthy dividend payout of 67.9%
Weaknesses
- −Promoter holding has decreased over last 3 years: -34.4%
Shareholding Pattern
Promoters65.57%
FIIs2.81%
DIIs6.84%
Public24.79%
| Category | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 65.57% | 65.57% | 65.57% | 65.57% | 65.57% | 65.57% | 65.57% | 65.57% |
| FIIs | 5.38% | 4.7%▼0.7 | 4.71%▲0.0 | 4.49%▼0.2 | 4.96%▲0.5 | 3.2%▼1.8 | 2.73%▼0.5 | 2.81%▲0.1 |
| DIIs | 11.88% | 10.8%▼1.1 | 11.3%▲0.5 | 11.35%▲0.0 | 9.33%▼2.0 | 6.45%▼2.9 | 6.2%▼0.3 | 6.84%▲0.6 |
| Public | 17.16% | 18.92%▲1.8 | 18.41%▼0.5 | 18.59%▲0.2 | 20.14%▲1.6 | 24.77%▲4.6 | 25.48%▲0.7 | 24.79%▼0.7 |
Financial Statements
| Metric | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 107.98 | 96.59 | 99.43 | 97.82 | 105.66 | 102.21 | 101.4 | 107.11 | 118.91 | 120.16 |
| Expenses | 83.39 | 75.59 | 76.26 | 79.85 | 82.23 | 80.95 | 80.7 | 89.74 | 96.17 | 99.45 |
| Operating Profit | 24.59 | 21 | 23.17 | 17.97 | 23.43 | 21.26 | 20.7 | 17.37 | 22.74 | 20.71 |
| OPM % | 22.77% | 21.74% | 23.3% | 18.37% | 22.17% | 20.8% | 20.41% | 16.22% | 19.12% | 17.24% |
| Net Profit | 13.5 | 11.47 | 12.82 | 9.96 | 14.82 | 12.25 | 12.89 | 7.68 | 10.6 | 9.37 |
| EPS ₹ | 1.69 | 1.44 | 1.56 | 1.21 | 1.81 | 1.49 | 1.57 | 0.94 | 1.29 | 1.14 |
AI Insights
Revenue Trend
TTM revenue at ₹448Cr, up 10.1% YoY. OPM at 18%.
Debt Position
Borrowings at ₹97Cr. Debt-to-equity ratio: 0.56x. Moderate leverage.
Capex Cycle
CWIP at ₹2Cr (1% of fixed assets). Moderate ongoing capital expenditure.
Institutional Flow
DIIs: 6.84% (-4.77pp change). FIIs: 2.81% (-3.87pp change). Promoters hold 65.57%.
Margin & Efficiency
ROCE improving from 0% (Mar 2020) to 27% (Mar 2025). Working capital days: -28.
Valuation
PE 28x with 27.2% ROCE. Price is 347% above book value of ₹30.9. Dividend yield: 1.83%.
Recent Announcements
- Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 11 May - Intimation of earnings call for the 4th quarter and financial year ended March 31, 2026.
- Board Meeting Intimation for Approval Of Audited Results And Recommendation Of Final Dividend, If Any. 11 May - Board meets May 18, 2026 to approve audited Q4/FY26 results and consider final dividend.
- Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 10 Apr - Submitted Regulation 74(5) certificate for quarter ended March 31, 2026; no demat/remat requests received.
- Announcement under Regulation 30 (LODR)-Change in Management 2 Apr - Debashis Dhar resigned as Senior VP and Chief Business Development Officer, effective April 2, 2026.
- Closure of Trading Window 26 Mar
- Financial Year 2025 from bse
- Financial Year 2024 from bse
- Rating update 27 Oct 2025 from crisil